Enhanced Genomics has secured an additional funding round, bringing its total Series A financing to $19 million as the Cambridge-based biotech pushes forward with its internal pipeline of therapeutics for autoimmune and other common diseases.

The latest investment comes from BGF, Parkwalk and Meltwind. Enhanced said the funds will be used to expand programmes in conditions such as inflammatory bowel disease while also scaling output through pharma and biotech partnerships.

The company claims to be the only biotechnology group able to source genetically validated targets for complex genetic diseases where there is high unmet medical need. Its proprietary 3D multi-omics platform integrates genome-wide 3D interaction maps with disease-associated data to define causal biology in the most relevant cell types.

By translating these datasets into actionable insights, Enhanced is seeking to improve the probability of success in drug discovery while cutting the time and cost required to reach clinical development.

Dietrich Stephan, chair of Enhanced Genomics, said: “Our founders have led the field by developing technology to map 3D interactions on a whole-genome scale, and integrating these data with comprehensive multi-omics datasets. We now have the technological capabilities to decipher the causal biology that drives complex and common genetic diseases, with the potential to develop truly effective new blockbuster therapies.

“This puts us in a strong position to lead the next major shift in pharma. When developing a novel approach to drug discovery, clarity of thought and courage are required to build deep conviction, and we are proud to have built a team that embodies this. We thank our investors for continuing to support our vision.”

Enhanced is targeting both internal drug discovery and collaborations, with the aim of building partnerships around novel target identification and asset-based opportunities. The focus is on high-value indications including autoimmune disease, where many existing therapies only provide partial benefit.

The latest financing follows earlier backing in the Series A and reflects sustained investor confidence despite a constrained funding environment for early-stage biotech. The company argues its approach, grounded in strong genetic validation, can address one of the key causes of attrition in pharmaceutical R&D.